Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
The MHRA agreed that reliance on the substantial body of historic nonclinical and clinical evidence for CBD, alongside legacy data for TMP, provides a scientifically justified basis for a streamlined clinical trial application (CTA)-enabling nonclinical development plan of the cocrystal combination to support the proposed FIH study, with clear guidance for achieving the agreed-upon FIH study design for ART12.11. The agency also affirmed that the proposed first-in-human (FIH) study design—a single-dose, multi-formulation crossover study—was methodologically sound for characterizing ART12.11's pharmacokinetic profile. Importantly, the MHRA offered constructive and specific guidance for completing the data package supporting the agreed-upon Phase 1 trial.
Additionally, the agency proposed that ART12.11 may be a candidate for the Innovative Licensing and Access Pathway (ILAP). ILAP offers a unique opportunity to accelerate the development and patient access of promising new therapies through early and sustained collaboration with the MHRA, National Health Service, and health technology assessment bodies. Given ART12.11's novel mechanism and potential to address unmet needs in anxiety and depression, Artelo believes the program aligns well with ILAP's criteria and will evaluate a formal application to enter the pathway in the coming months.
'It's gratifying to receive this positive feedback and actionable recommendations from the MHRA, which provides a clear path forward as we prepare to initiate clinical studies with ART12.11,' said Dr. Andrew Yates, Chief Scientific Officer at Artelo. 'The recommendation to explore ILAP reinforces the proposition of ART12.11 as a novel drug with the potential to transform the treatment landscape for anxiety and depression.'
Multiple nonclinical studies with ART12.11 have shown its promising profile compared to an antidepressant or CBD alone. The Company recently announced positive preclinical results in a depression model comparing ART12.11 with sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), where Artelo's patented CBD:TMP cocrystal demonstrated efficacy on par with sertraline and showed superior cognitive restoration compared to the leading SSRI. Additionally, in a rodent model of stress-induced anxiety and depression, where ART12.11 was compared to CBD dosed at 300% the amount of CBD contained in the oral tablet of ART12.11, the CBD:TMP cocrystal demonstrated efficacy where CBD alone did not.
'The clear regulatory assurance from the regulatory authority in the UK is expected to reduce expenses for our ART12.11 program,' added Gregory Gorgas, President & CEO at Artelo. 'We are especially pleased with the potential for an accelerated development strategy which could greatly accelerate our progress with ART12.11 and could provide for a longer period of market exclusivity as our patents are valid in 20 countries through the end of 2038. Over the next few months we look forward to finalizing our preparations to enter the clinic with ART12.11 early next year.'
About ART12.11
ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Greatly enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile in a solid dosage form may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The U.S. issued composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has now been granted or validated in 19 additional countries.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
116-space Bradford city centre car park to be sold at auction
A 116-space Council-owned car park in Bradford city centre will go to auction later this month with a £160,000 guide price. The Burnett Street pay and display car park at the top of Little Germany was recently listed as one of the scores of assets that Bradford Council plans to sell in a bid to balance its books. On August 26, the car park will be included as a lot in an online property auction by Pugh. The car park that will go under the hammer (Image: Pugh) The site is one of the larger Council-operated car parks in the city centre, and is next to several of Little Germany's many listed buildings. The listing describes the lot as "a city-centre, freehold plot of land extending to approximately 0.87 acres (0.56 hectares)". The car park that will go under the hammer (Image: T&A) 'The plot is an irregular shape and comprises a hard-standing car park," it adds. 'The plot benefits from road frontage to both Barkerend Road and Shipley Airedale Road (A650), and is located approximately 0.5 miles east of Bradford city centre.' The online auction ends on Wednesday, August 27.
Yahoo
an hour ago
- Yahoo
FTI Consulting Expands Forensic and Litigation Consulting Segment in Asia with Appointment of Martin Tupila as Senior Managing Director
SINGAPORE, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the continued growth of its Forensic and Litigation Consulting segment in Asia with the appointment of Martin Tupila as a Senior Managing Director, based in Singapore. Mr. Tupila brings more than 20 years of experience in forensic accounting, financial investigations, regulatory enforcement and compliance advisory across Asia, Europe and Australia. He has supported multinational organisations, law firms and regulatory bodies on high-profile matters involving fraud, corruption, accounting irregularities and financial misstatement. In his role at FTI Consulting, Mr. Tupila will work closely with clients to address allegations involving accounting improprieties, conflicts of interest, misappropriation of assets and circumvention of regulations. He will collaborate with FTI Consulting's Asia-based team of forensic accountants, financial experts, data analysts, technologists, statisticians, economists and business intelligence professionals to analyse complex data and apply proven investigative and forensic accounting methods to support legal teams and act as an independent investigator and expert. 'Martin's appointment reinforces our commitment to growing our forensic capabilities in Asia and further deepens our regional bench strength,' said Michael Cullen, a Senior Managing Director and Leader of Asia and Latin America for the Forensic and Litigation Consulting segment. 'His proven track record advising clients on sensitive and high-stakes matters makes him a valuable addition to our team. I look forward to working alongside Martin as we continue to help clients protect enterprise value and respond confidently to regulatory and legal challenges.' Prior to joining FTI Consulting, Mr. Tupila led the ASEAN claims and disputes practice at a global accounting firm and headed the greater China forensic practice at a leading advisory firm. His extensive regional experience and cross-sector expertise strengthen FTI Consulting's ability to support clients navigating complex disputes and investigations across Asia. The addition of Mr. Tupila continues FTI Consulting's investment in the Forensic and Litigation Consulting segment, following the recent appointments of Senior Managing Directors Rosie Hawes and Andrew Macintosh in Singapore, enhancing the firm's ability to deliver multidisciplinary expertise in forensic accounting, investigations, data analytics and regulatory compliance. About FTI Consulting FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 7,900 employees located in 32 countries and territories as of June 30, 2025. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at FTI Consulting, Inc. 555 12th Street NWWashington, DC 20004 +1.202.312.9100 Investor Contact:Mollie Hawkes+ Media Contact:Andrew Gerrard+852 376 84562 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
an hour ago
- Epoch Times
Chinese Academic Repression Distorts the UK's China Studies, Survey Finds
The Chinese Communist Party (CCP) is distorting the UK's China studies system with widespread influence, interference, and harassment, a survey found. In a report published Aug. 3, London-based charity UK-China Transparency (UKCT) said it found strong evidence that CCP influence in British universities is 'shaping careers and disincentivising certain research and other activity that might be negatively received by the CCP.'
